Evogene Shareholders Approve Proposals, Reject CEO Stock Options
Ticker: EVGN · Form: 6-K · Filed: Jun 17, 2024 · CIK: 1574565
Sentiment: neutral
Topics: shareholder-meeting, corporate-governance, executive-compensation
TL;DR
Evogene shareholders said yes to everything except CEO stock options at the June 13th meeting.
AI Summary
Evogene Ltd. held its annual general meeting of shareholders on June 13, 2024, where all proposals were approved, except for the resolution regarding the grant of options to the CEO. The company is incorporated in Israel and operates in the agriculture chemicals sector.
Why It Matters
Shareholder approval of proposals is crucial for corporate governance and the execution of the company's strategic plans. The rejection of CEO stock options may signal shareholder concerns about executive compensation.
Risk Assessment
Risk Level: low — The filing is a routine 6-K report announcing the results of a shareholder meeting, with no new material financial or operational information that would typically increase risk.
Key Players & Entities
- Evogene Ltd. (company) — Registrant
- June 13, 2024 (date) — Annual general meeting date
- CEO (person) — Recipient of rejected stock option grant
FAQ
What was the outcome of the annual general meeting of shareholders held on June 13, 2024?
All proposals brought before the meeting were approved by the shareholders, with the exception of the resolution concerning the grant of options to the CEO.
Which specific proposal was rejected by Evogene's shareholders?
The resolution with respect to the grant of options to the CEO was rejected by the shareholders.
When was Evogene Ltd.'s annual general meeting of shareholders held?
The annual general meeting of shareholders was held on June 13, 2024.
What is Evogene Ltd.'s primary business sector?
Evogene Ltd. is in the AGRICULTURE CHEMICALS sector, with SIC code 2870.
What form does Evogene Ltd. file annually?
Evogene Ltd. files its annual reports under cover of Form 20-F.
Filing Stats: 338 words · 1 min read · ~1 pages · Grade level 13.6 · Accepted 2024-06-17 16:10:30
Filing Documents
- zk2431583.htm (6-K) — 9KB
- 0001178913-24-001995.txt ( ) — 10KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2024 Commission File Number 001-36187 EVOGENE LTD. (Translation of Registrant's Name into English) 13 Gad Feinstein Street, Park Rehovot, Rehovot 7638517, Israel (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F CONTENTS Evogene Ltd. (the " Registrant " or the " Company ") hereby announces that, excluding the resolution with respect to grant of options to our CEO, which was rejected, the shareholders of the Company approved all the proposals brought before the annual general meeting of shareholders held on June 13, 2024 (following a one-week adjournment from the original meeting date) (the " Meeting "), by the respective requisite majority in accordance with the Israeli Companies Law, 5759-1999, and the Company's articles of association, as described in the Proxy Statement which was attached as Exhibit 99.2 to the Company's Report of Foreign Private Issuer on Form 6-K, furnished to the Securities and Exchange Commission (" SEC "), on April 30, 2024, and sent in connection with the Meeting. The contents of this Report of Foreign Private Issuer on Form 6-K (this " Form 6-K ") is incorporated by reference in the registration superseded by documents or reports subsequently filed or furnished. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: June 17, 2024 EVOGENE LTD. (Registrant) By: /s/ Yaron Eldad —————————————— Yaron Eldad Chief Financial Officer